Clinical Trials Browser

INDUSTRY × cabozantinib × Gastrointestinal × Clear all

NCT03798626 2026-01-27

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT06026410 2026-01-02

FIT-001

Phase 1 Recruiting

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Colorectal Neoplasms

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03755791 2025-12-11

COSMIC-312

Phase 3 Active not recruiting

837 enrolled 14 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00940225 2024-04-25

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Phase 2 Completed

730 enrolled 25 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT01908426 2021-05-06

CELESTIAL

Phase 3 Completed

707 enrolled 20 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms